Invion (IVIXF)
OTHER OTC:IVIXF
Want to see IVIXF full AI Analyst Report?
IVIXF Stock Chart & Stats
$0.04
$0.00(0.00%)
At close: 4:00 PM EST
$0.04
$0.00(0.00%)
Day’s Range― - ―
52-Week Range$0.04 - $0.04
Previous CloseN/A
Volume2.00
Average Volume (3M)0.00
Market Cap
$4.33M
Enterprise Value$6.60M
Total Cash (Recent Filing)$137.54K
Total Debt (Recent Filing)$627.68K
Price to Earnings (P/E)―
Beta-3.20
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding96,965,320
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.96
Price to Sales (P/S)0.00
P/FCF Ratio-2.67
Enterprise Value/Market Cap1.52
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-4.15
Enterprise Value/Ebitda-1.28
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Leverage (no Debt)No reported debt reduces fixed financial obligations and interest burden, preserving optionality for R&D spending and fundraising. For a small biotech, having no leverage is a durable risk mitigant that supports runway extension and flexibility in structuring future partner or equity financings.
Partner-funded R&D And Licensing Revenue ModelReliance on development funding and milestone-based licensing is a structural strength for a pre-commercial biotech: it shifts early-stage cost and execution risk to partners, creates non-dilutive milestone inflows, and aligns incentives with larger collaborators, improving sustainability versus sole self-funding.
Proprietary PDT Tech And Research CollaborationsOwning a proprietary photodynamic therapy platform plus active collaborations with research institutions builds durable competitive differentiation. IP and academic validation increase licensing appeal, enable trial access, and support pathway-to-market options that persist beyond short-term financial cycles.
Bears Say
Revenue Collapse And Widening LossesA drop to zero reported revenue and materially larger net losses signal a structural deterioration in commercial traction or partner funding. This undermines internal financing capability, amplifies reliance on external capital, and raises viability risk for ongoing programs over the medium term.
Persistent Negative Operating Cash FlowRepeated negative operating cash flow shows core operations are not self-sustaining. Ongoing cash burn forces regular fundraising, which can dilute shareholders, constrain development cadence, and increase the chance of program delays or prioritization shifts if capital access tightens over the next several quarters.
Shrinking Equity And Asset BaseDeclining equity and shrinking assets reduce balance-sheet resilience and financial flexibility. With fewer tangible resources and deteriorating net assets, the company faces higher funding risk and weaker bargaining power with partners and lenders, elevating structural refinancing and solvency concerns.
Invion News
IVIXF FAQ
What was Invion’s price range in the past 12 months?
Invion lowest stock price was $0.04 and its highest was $0.04 in the past 12 months.
What is Invion’s market cap?
Invion’s market cap is $4.33M.
When is Invion’s upcoming earnings report date?
Invion’s upcoming earnings report date is Aug 27, 2026 which is in 114 days.
How were Invion’s earnings last quarter?
Invion released its earnings results on Feb 26, 2026. The company reported -$0.03 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.03.
Is Invion overvalued?
According to Wall Street analysts Invion’s price is currently Overvalued.
Does Invion pay dividends?
Invion does not currently pay dividends.
What is Invion’s EPS estimate?
Invion’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Invion have?
Invion has 96,965,320 shares outstanding.
What happened to Invion’s price movement after its last earnings report?
Invion reported an EPS of -$0.03 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Invion?
Currently, no hedge funds are holding shares in IVIXF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Invion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.00%
12-Months-Change
Fundamentals
Return on Equity
-150.48%
Trailing 12-Months
Asset Growth
-37.10%
Trailing 12-Months
Company Description
Invion
Invion Limited, a clinical-stage life-sciences company, researches and develops photodynamic therapy for the treatment of various cancers in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, as well as solid cancers, including lung, prostrate, ovarian, and mesothelioma cancers. It has a research and development agreement with Hudson Institute of Medical Research to collaborate on a range of research and development projects for the Photosoft technology for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion's IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer. The company was incorporated in 2000 and is headquartered in Melbourne, Australia.
Technical Analysis
Percheron Therapeutics
―
Argent Biopharma
―
Medical Developments International Limited
―
Althea Group Holdings Ltd.
―
IDT Australia Limited
―
Ownership Overview
Options Prices
Currently, No data available
---